RE:RE:Lesson from ESPRJD, I was simply pointing out that I was shocked at how the PPS climbed so much for ESPR and was wondering if this recent event is foretelling of how the market is treating other small cap biotech in this cardiovascular/metabolism field right now. Is $100 a reasonable price for ESPR or is it overvalued? I think ESPR is overvalued right now personally. So based on how the market "overvalued" ESPR after its recent phase IIs, would the market behave the same for other biotechs in this area, including but not limited to RVX. Although RVX has increased 650% relative to its 52-week low as you indicated, it is basically back to its pre-ASSURE news release/post-Zentih spin off value. So my post was not as much about RVX pumping/speculation but more not understanding why ESPR jumped so much.